Protocol for the systematic reviews on the desirable and undesirable effects of pharmacological treatments of allergic rhinitis informing the ARIA 2024 guidelines

• Type: Article in International Scientific Journal
• Date: 2024

Authors

Vieira, RJ (Author) FMUP; Torres, MI (Author) Other; Bognanni, A (Author) Other; Gil-Mata, S (Author) Other; Ferreira-da-Silva, R (Author) FMUP; Lourenço-Silva, N (Author) Other; Cardoso-Fernandes, A (Author) FMUP; Ferreira, A (Author) Other; Ferreira-Cardoso, H (Author) Other; Teles, J (Author) Other; Campos-Lopes, M (Author) Other; Fonseca, JA (Author) Other; Yepes-Nuñez, JJ (Author) Other; Klimek, L (Author) Other; Zuberbier, T (Author) Other; Schünemann, H (Author) Other; Bousquet, J (Author) Other; Sousa-Pinto, B (Author) FMUP

Journal

The Journal is awaiting validation by the Administrative Services.

Title: ALLERGOLOGIE SELECT

Vol. 8

Pages: 270-277

ISSN: 2512-8957

Indexing

ISI Web of Knowledge - 3 Citations

Other information

Authenticus ID: P-011-3BY

DOI: 10.5414/alx02515e

Abstract (EN): There is insufficient evidence regarding the comparative efficacy and safety of pharmacological treatments of allergic rhinitis (AR). In the context of informing the 2024 revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, we plan to perform three systematic reviews of randomized controlled trials (RCTs) comparing the desirable and undesirable effects (i) between intranasal and oral medications for AR; (ii) between combinations of intranasal and oral medications versus nasal or oral medications alone; and (iii) among different intranasal specific medications. We will search four electronic bibliographic databases and three clinical trials databases for RCTs examining patients >= 12 years old with seasonal or perennial AR. Assessed outcomes will include the Total Nasal Symptom Score, the Total Ocular Symptom Score, and the Rhinoconjunctivitis Quality-of-Life Questionnaire. We will assess the methodological quality of included primary studies by using the Cochrane risk-of-bias tool. If appropriate, we will perform a pairwise random-effects meta-analysis for each pair of assessed medication classes and outcomes, as well as a network meta-analysis to assess the comparative efficacy of intranasal medications among each other. Heterogeneity will be explored by sensitivity and subgroup analyses. This set of systematic reviews will allow for a comprehensive assessment of the effectiveness and safety of pharmacological interventions for AR and inform recommendations in the context of the ARIA guidelines.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 8